INCY$120.060.27%-0.33
After Hours: 120.04-0.02 -0.02%
Incyte Corp (INCY)
Date: 2026-11-02 16:00O: 119.02H: 121.52L: 118.25C: 120.06Vol: 1.282M
Incyte Corp stock is traded at $120.06, with a volume of 1,282,283. It is down -0.27% in the last 24 hours and up +4.13% over the past month. Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
Previous Close:
$120.39
Open:
$119.02
24h Volume:
1,282,283
Relative Volume:
0.63
Market Cap:
$24.47B
Revenue:
$5.36B
Net Income/Loss:
$1.43B
P/E Ratio:
16.98
EPS:
$7.07
Net Cash Flow:
$1.42B
1W Performance:
+5.96%
1M Performance:
+4.13%
6M Performance:
+23.89%
1Y Performance:
+28.43%
1-Day Range:
$118.25$121.52
1-Week Range:
$111.01$122.87
52-Week Range:
$89.25$132.60
Incyte Corp Stock (INCY) Company Profile
Name
Incyte CorpSector
HealthcareIndustry
BiotechnologyPhone
(302) 498-6700Address
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE, USACompare INCY vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|
INCY Incyte Corp | $24.47B | $6.01B | $403.41M | $892.11M | $7.07 |
 VRTX Vertex Pharmaceuticals Inc | $140.94B | $12.59B | $4.41B | $3.80B | $16.87 |
 REGN Regeneron Pharmaceuticals Inc | $99.46B | $16.90B | $4.82B | $3.83B | $41.04 |
 MRNA Moderna Inc | $88.17B | $2.23B | -$3.15B | -$1.24B | -$8.15 |
 ARGX Argen X Se Adr | $55.03B | $4.16B | $1.29B | $734.26M | $19.58 |
 ONC Beone Medicines Ltd Adr | $40.86B | $6.13B | $655.71M | $1.33B | $4.48 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
Incyte Corp Stock (INCY) Financials Data
Incyte Corp Stock (INCY) Insider Trading
- CAGNONI PABLO JOct 15 '26President, Global Head of R&D
- Transaction
- Sale
- Cost
- $112.71
- #Shares
- 2,642
- Value ($)
- 297,780
- #Shares Total
- 183,200
- CAGNONI PABLO JOct 15 '26President, Global Head of R&D
- Transaction
- Option Exercise
- Cost
- $65.76
- #Shares
- 2,642
- Value ($)
- 173,742
- #Shares Total
- 185,842
- PABLO CAGNONIOct 15 '26Officer
- Transaction
- Proposed Sale
- Cost
- $112.71
- #Shares
- 2,642
- Value ($)
- 297,780
- #Shares Total
- 0
- PABLO CAGNONISep 15 '26Officer
- Transaction
- Proposed Sale
- Cost
- $120.49
- #Shares
- 23,218
- Value ($)
- 2,797,571
- #Shares Total
- 0
- CAGNONI PABLO JSep 15 '26President, Global Head of R&D
- Transaction
- Sale
- Cost
- $120.49
- #Shares
- 23,218
- Value ($)
- 2,797,629
- #Shares Total
- 183,200
- CAGNONI PABLO JSep 15 '26President, Global Head of R&D
- Transaction
- Option Exercise
- Cost
- $66.39
- #Shares
- 23,218
- Value ($)
- 1,541,331
- #Shares Total
- 206,418
- CAGNONI PABLO JAug 19 '26President, Global Head of R&D
- Transaction
- Sale
- Cost
- $125.56
- #Shares
- 10,801
- Value ($)
- 1,356,174
- #Shares Total
- 183,200
- PABLO CAGNONIAug 19 '26Officer
- Transaction
- Proposed Sale
- Cost
- $125.56
- #Shares
- 10,801
- Value ($)
- 1,356,190
- #Shares Total
- 0
- PABLO CAGNONIAug 12 '26Officer
- Transaction
- Proposed Sale
- Cost
- $120.04
- #Shares
- 10,803
- Value ($)
- 1,296,774
- #Shares Total
- 0
- CAGNONI PABLO JAug 12 '26President, Global Head of R&D
- Transaction
- Sale
- Cost
- $120.04
- #Shares
- 10,803
- Value ($)
- 1,296,792
- #Shares Total
- 194,001
